| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-12-15 | Valneva (France - Austria) | €7.5 million | private placement | MVM Life Science Partners (UK) | Infectious diseases - Veterinary medicine - Technology - Services | Private placement |
| 2016-12-14 | Acousia Therapeutics (Germany) | € 2.5 million | financing round | Boehringer Ingelheim Venture Fund (BIVF) (Germany) KfW (Germany) Axxam (Italy) | Otorhinolaryngology | Financing round |
| 2016-12-13 | CytRx Corporation (USA - CA) | $7.4 million | private placement | existing institutional investors | Cancer - Oncology | Private placement |
| 2016-12-12 | BlueRock Therapeutics (USA - Canada) | $ 225 million | series A financing round | Bayer Healthcare (Germany) Versant Ventures (USA - CA) | Cardiovascular diseases - Neurodegenerative diseases | Series A financing round |
| 2016-12-12 | Herantis Pharma (Finland) TreatER project | € 6 million | grant | European Commission’s Horizon 2020 programme | CNS diseases - Neurological diseases | Grant |
| 2016-12-12 | EURE-CART (EURopean Endeavour for Chimeric Antigen Receptor Therapies) project coordinated by Molmed (Italy) | € 5.9 million | grant | European Commission’s Horizon 2020 programme | Cancer - Oncology | Grant |
| 2016-12-05 | Ixchelsis (UK) | $ 12 million | financing round | TVM Life Science VII (Canada) Pfizer Venture Investments (USA - NY) | Urological diseases | Financing round |
| 2016-12-02 | Cerevance (USA - MA) | $36 million | series A financing round | Takeda Pharmaceutical (Japan) Lightstone Ventures (USA - CA) | CNS diseases - Mental diseases - Neurological diseases | Series A financing round |
| 2016-12-02 | Amryt Pharma (Ireland) | € 20 million | loan | European Investment Bank (EIB) | Rare diseases | Loan |
| 2016-12-01 | Inovio Pharmaceuticals (USA - PA) | $6.1 million | grant | Infectious diseases | Grant | |
| 2016-11-29 | Cytune Pharma (France) | € 6 million | financing round | PPF Group (Czech Republic) founding shareholders | Cancer - Oncology - Infectious diseases | Financing round |
| 2016-11-24 | Kymab (UK) | $100 million (£81 million) | series C financing round | ORI Fund (China) Hepalink Pharmaceutical (China) Wellcome Trust (UK) Bill & Melinda Gates Foundation (USA) Malin Corporation (UK) CF Woodford Equity Income Fund (UK) Woodford Patient Capital (UK) | Series C financing round | |
| 2016-11-23 | Orchard Therapeutics (UK) University of California, Los Angeles (USA - CA) | $20 million | grant | California’s stem cell agency (USA - CA) | Rare diseases - Genetic diseases | Grant |
| 2016-11-22 | Fate Therapeutics (USA - CA) | $57 million | private placement | Cancer - Oncology - Immunological diseases | Private placement | |
| 2016-11-16 | Glycomine (USA - CA) | $12 million | series A financing round | Chiesi Ventures (USA - MA) Sanderling Ventures (USA - CA) existing high net worth individuals and patients | Rare diseases - Genetic diseases | Series A financing round |
| 2016-11-15 | Morphosys (Germany) | € 115 million | private placement | Cancer - Oncology - Inflammatory diseases | Private placement | |
| 2016-11-10 | Transgene (France) | €46.4 million | capital increase | Institut Mérieux (France) | Cancer - Oncology - Infectious diseases | Capital increase |
| 2016-11-09 | Merus (The Netherlands) Aquila BioMedical (UK) | €1.5 million | grant | European Eurostars Programme (EU) | Cancer - Oncology | Grant |
| 2016-11-08 | Curevac (Germany) | $29.5 million | financing round | Baden-Württembergische Versorgungsanstalt für Ärzt (Germany) Zahnärzte und Tierärzte (via the LBBW Asset Management Investmentgesellschaft (Germany) Landeskreditbank Baden-Württemberg (Germany) | Financing round | |
| 2016-11-04 | Plasticell (UK) | £1.32 million (€1.48 million) | financing round | Cancer - Oncology | Fundraising |
